Actively Recruiting
Evaluation of 68Ga-P3 PETCT Imaging Targeting PSMA in Men with Suspected or Confirmed Prostate Cancer
Led by Peking University First Hospital · Updated on 2024-11-07
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Prostate-specific membrane antigen PSMA is a protein highly present on most prostate cancer cells and tumor blood vessels, making it an important target for cancer imaging. Researchers are evaluating a new PET imaging agent called 68GaP3, which specifically targets PSMA, to improve the diagnosis and study of cancers that show high PSMA expression. In this study, participants with suspected or confirmed prostate cancer will receive an intravenous injection of 68GaP3 at a dose between 0.06 and 0.08 mCikg. After injection, they will undergo PETCT imaging to assess PSMA expression. This imaging technique is being studied for its ability to detect prostate cancer and evaluate its characteristics. Participants will be involved in PETCT scans following the injection of 68GaP3. Researchers will evaluate the diagnostic and detection effectiveness of this imaging agent over one year. Additional assessments include measuring the radiation dose participants receive, quantitative analysis of the imaging agent, and correlating imaging findings with pathological results. The total study duration and follow-up are planned for one year.
CONDITIONS
Brief Title
68Ga-P3 PET/CT Imaging in Prostate
Research Team
X
Xing Yang, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
